Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Clinical and economic burden of breakthrough seizures.

Divino V, Petrilla AA, Bollu V, Velez F, Ettinger A, Makin C.

Epilepsy Behav. 2015 Aug 5;51:40-47. doi: 10.1016/j.yebeh.2015.06.013. [Epub ahead of print]

PMID:
26255884
2.

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.

J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.

PMID:
25019581
3.

Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.

Trocio JN, Brubaker L, Schabert VF, Bavendam T, Chen CI, Zou KH, Petrilla AA, Burgio KL.

Postgrad Med. 2014 May;126(3):246-56. doi: 10.3810/pgm.2014.05.2773.

PMID:
24918809
4.

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.

Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, McGuiness CB, Korn JR.

PLoS One. 2014 Feb 6;9(2):e88472. doi: 10.1371/journal.pone.0088472. eCollection 2014.

5.

The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis.

Pokras SM, Petrilla AA, Weatherall J, Lee WC.

Haemophilia. 2012 Mar;18(2):284-90. doi: 10.1111/j.1365-2516.2011.02623.x. Epub 2011 Aug 4.

PMID:
21812862
6.

Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.

Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS.

Am J Cardiovasc Drugs. 2009;9(5):299-308. doi: 10.2165/11312110-000000000-00000.

PMID:
19791839
7.

Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.

Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS.

Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7. doi: 10.2146/ajhp080238.

PMID:
19667004
8.

Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study.

Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS.

Drugs Aging. 2008;25(10):885-92.

PMID:
18808213
9.

Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States.

Benner JS, Smith TW, Petrilla AA, Klingman D, Goel S, Tang SS, Wong ND.

J Am Soc Hypertens. 2008 Jan-Feb;2(1):44-53. doi: 10.1016/j.jash.2007.07.001.

PMID:
20409884
10.

Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications.

Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH.

Int J Clin Pract. 2005 Dec;59(12):1441-51. Review.

PMID:
16351677
11.
12.

Predictors of adherence with antihypertensive and lipid-lowering therapy.

Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS.

Arch Intern Med. 2005 May 23;165(10):1147-52.

PMID:
15911728
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk